EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer

Samantha M Sarrett, Cindy Rodriguez, Samantha Delaney, Meena M Hosny, Joni Sebastiano, Ana Santos-Coquillat iD, Outi M Keinänen iD, Lukas M Carter, Kristin J Lastwika, Paul D Lampe, Brian M Zeglis iD

Molecular Pharmaceutics · 04.03.2024 · 21 (3) · 1402-1413

DOI: 10.1021/acs.molpharmaceut.3c01063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 08.02.2024. Verfasst von Samantha M Sarrett und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite decades of work, small-cell lung cancer (SCLC) remains a frustratingly recalcitrant disease. Both diagnosis and treatment are challenges: low-dose computed tomography (the approved method used for lung cancer screening) is unable to reliably detect early SCLC, and the malignancy's 5 year survival rate stands at a paltry 7%. Clearly, the development of novel diagnostic and therapeutic tools for SCLC is an urgent, unmet need. CD133 is a transmembrane protein that is expressed at low levels in normal tissue but is overexpressed by a variety of tumors, including SCLC. We previously explored CD133 as a biomarker for a novel autoantibody-to-immunopositron emission tomography (PET) strategy for the diagnosis of SCLC, work that first suggested the promise of the antigen as a radiotheranostic target in the disease. Herein, we report the in vivo validation of a pair of CD133-targeted radioimmunoconjugates for the PET imaging and radioimmunotherapy of SCLC. To this end, [89Zr]Zr-DFO-αCD133 was first interrogated in a trio of advanced murine models of SCLC─i.e., orthotopic, metastatic, and patient-derived xenografts─with the PET probe consistently producing high activity concentrations (>%ID/g) in tumor lesions combined with low uptake in healthy tissues. Subsequently, a variant of αCD133 labeled with the β-emitting radiometal 177Lu─[177Lu]Lu-DTPA-A″-CHX-αCD133─was synthesized and evaluated in a longitudinal therapy study in a subcutaneous xenograft model of SCLC, ultimately revealing that treatment with a dose of 9.6 MBq of the radioimmunoconjugate produced a significant increase in median survival compared to a control cohort. Taken together, these data establish CD133 as a viable target for the nuclear imaging and radiopharmaceutical therapy of SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaHumansAnimalsMiceEarly Detection of CancerCell Line, TumorPositron-Emission Tomography

Stichwörter der Autor:innen

CD133PET imagingmetastatic xenograftorthotopic xenograftpatient-derived xenograftradioimmunotherapysmall-cell lung cancer

Autor:innen und Institutionen

  • Department of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States.
  • Ph.D. Program in Biochemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
  • Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States.
  • Department of Chemistry, CICECO─Aveiro Institute of Materials, University of Aveiro, Campus Universitario de Santiago, Aveiro 3810-193, Portugal.
  • Department of Chemistry, University of Helsinki, Helsinki 00100, Finland.

ORCID-Profile: Ana Santos-Coquillat, Outi M Keinänen, Brian M Zeglis

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NCRR NIH HHS
  • NIEHS NIH HHS
  • NIAID NIH HHS
  • National Cancer Institute

Zitieren

APA

Sarrett, S. M., Rodriguez, C., Delaney, S., Hosny, M. M., Sebastiano, J., Santos-Coquillat, A., Keinänen, O. M., Carter, L. M., Lastwika, K. J., Lampe, P. D., & Zeglis, B. M. (2024). Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer. Molecular Pharmaceutics, 21(3), 1402-1413. https://doi.org/10.1021/acs.molpharmaceut.3c01063

Vancouver

Sarrett SM, Rodriguez C, Delaney S, Hosny MM, Sebastiano J, Santos-Coquillat A, et al. Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer. Molecular Pharmaceutics. 2024;21(3):1402-1413. doi:10.1021/acs.molpharmaceut.3c01063

BibTeX
@article{Sarrett2024,
  author = {Sarrett, Samantha M and Rodriguez, Cindy and Delaney, Samantha and Hosny, Meena M and Sebastiano, Joni and Santos-Coquillat, Ana and Keinänen, Outi M and Carter, Lukas M and Lastwika, Kristin J and Lampe, Paul D and Zeglis, Brian M},
  title = {Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {3},
  pages = {1402--1413},
  doi = {10.1021/acs.molpharmaceut.3c01063}
}
Kostenlos starten →